BioGenCell is led by a team of seasoned executives who have many years of executive and technical experience in the biotechnology industry. The founding team has a proven track record in the creation and manufacturing of commercially available cellular products, which were proven safe and beneficial for treating severe heart diseases and peripheral arterial diseases.

  • Yael Porat, PhD – CEO, Founder

    Dr. Porat is a specialist in the biotechnology industry, having worked as an innovator, scientist, advisor and director for both industry leaders and pioneering startups.
    Prior to founding BioGenCell, Dr. Porat served as CTO for TheraVitae, where she established the R&D and manufacturing departments and was responsible for the research, development and production of the company’s GMP-compliant adult stem cell-based products used for preclinical and clinical studies, as well as for routine treatment of patients.
    Previously, Dr. Porat worked for the global R&D division of Teva Pharmaceutical Industries Ltd (Nasdaq: TEVA) as Manager of the Biological Methods Development department where she lead multidisciplinary research teams in development of biological methods supporting pharmaceutical products development. Prior to Teva, she worked for XTL Biopharmaceuticals Ltd (Nasdaq: XTLB) as a senior project manager and member of the project leaders forum in charge of the company’s strategic planning. Dr. Porat, an author of many scientific publications and patents, holds MA and PhD degrees in Immunology from the Sackler School of Medicine, Tel-Aviv University, Israel.

  • Prof. Michael Belkin, MD – Chief Scientific Officer, Co-Founder

    Prof. Belkin has been involved in biotechnology ventures since the creation of the field and was involved in the establishment of over 15 medical start-ups in ophthalmology and other fields. He also serves as a consultant to numerous biotechnology projects and companies.
    Prof. Belkin is currently a professor of Ophthalmology and the incumbent of the Fox Chair of Ophthalmology in Tel-Aviv University. He is also the director of the Ophthalmic Technologies Laboratory at the university’s Eye Research Institute located at the Sheba Medical Center, Israel, and serves as senior advisor to the Singapore Eye Research Institute.
    Prof. Belkin served previously as Director of Research, Development and Non-conventional Warfare Medicine in the Israel Defense Forces’ Medical Corps, was the first full-time director of the Tel Aviv University Eye Research Institute, Chairman of the Tel-Aviv University Department of Ophthalmology and President of the Israel Society of Eye and Vision Research of which he was a founder.
    Prof. Belkin, who is the author of over 200 scientific publications and holds 15 patents, received an MA in Science from Cambridge University, England, and a PhD in Medicine from the Hebrew University of Jerusalem, Israel.

  • Mr. Eyal Peleg, CPA, MBA – Chief Financial Officer, Co-Founder

    Mr. Peleg has over 25 years experience in growing and managing professional teams as a CEO. He is currently a consultant to both start-ups and established companies on the issues of strategic planning, business plans, long and short term contracts as well as  financial and tax planning programs and controlling.
    Prior to his CEO positions, Mr. Peleg was a senior partner in an accounting firm responsible for IPOs, evaluations, business plans and controlling. He is a director of several commercial and hi-tech companies and is a member of several national and industrial committees, in charge of national financial regulations.
    Mr. Peleg is a certified CPA and holds an MBA degree (financing) from the Recanati Business School of Tel Aviv University, Israel.

  • Michael Barnea, Adv. – Legal Advisor

    Mr. Barnea is a senior partner at the law firm of Barnea & Co., where he specializes in technology-related sales, licensing and development transactions, and has advised technology and investment companies on a variety of corporate transactions, including mergers and acquisitions, share purchases, private placements and public offerings on the Tel Aviv, London and Nasdaq stock exchanges.
    Mr. Barnea is a graduate of the Tel Aviv University Law School, and served as a teaching assistant at the Recanati Business School of Tel Aviv University, Israel.

  • Marc Dechamps – BioGenCell EU Administrator

    Marc Dechamps is a biologist with extensive experience of more than 30 years in the Pharmaceutical industry, with expertise in market development for new products including infectious diseases, immunological disorders, cancer, CNS diseases and vaccines. He started his career with sales and marketing management positions at corporate pharma companies including Glaxo, Glaxo Wellcome and GSK. His last position was Executive Director of the Commercial department “Specialty care & Vaccines” at GSK . In 2009 he became Head of the European Mid-Size Countries Region at ViiV Healthcare (ViiVHC), a spin out company created by GSK and Pfizer where he created and managed 4 ViiVHC Companies and built a European Commercial – Market Access Operations team dedicated to the launch of the new assets of ViiVHC. Since 2016 Mr. Dechamps has supported biotechnological start-up companies in the field of gene and cell therapies with strategic advising and management leadership. Before joining BioGenCell Marc served as Managing Director of Delphi Genetics, a Belgian Biotech company specialised in the production of plasmid DNA. Marc is also currently acting as Chairman of the Management Committee of eTheRNA, a “round A” Belgian biotech company, involved in Immuno-oncology, developing a specific mRNA platform for boosting the immune system.